shrinking 12% to €318 million amid pressure from newer drugs. Mavenclad (cladribine) added €89 million in the quarter – more than three times the €25 million reported a year ago – thanks ...

rash and difficulty breathing are listed the most common side effects with the Roche drug. Merck KGaA's recently approved MS pill Mavenclad (cladribine) is also available to NHS patients after the ...

NICE’s latest decision on the drug was supported by clinical and real-world evidence demonstrating that Mavenclad can reduce MS relapse rates and slow disability progression. The agency is now ...